These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37790486)

  • 1. First-in-human clinical trial of personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma.
    Kwak L; Szymura S; Wang L; Zhang T; Cha SC; Dong Z; Anderson A; Oh E; Lee V; Wang Z; Parshottham S; Rao S; Olsem J; Crumpton B; Lee H; Manasanch E; Neelapu S; Thomas S
    Res Sq; 2023 Sep; ():. PubMed ID: 37790486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial.
    Szymura SJ; Wang L; Zhang T; Cha SC; Song J; Dong Z; Anderson A; Oh E; Lee V; Wang Z; Parshottam S; Rao S; Olsem JB; Crumpton BN; Lee HC; Manasanch EE; Neelapu S; Kwak LW; Thomas SK
    Nat Commun; 2024 Aug; 15(1):6874. PubMed ID: 39128904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.
    Thomas SK; Cha SC; Smith DL; Kim KH; Parshottam SR; Rao S; Popescu M; Lee VY; Neelapu SS; Kwak LW
    BMC Cancer; 2018 Feb; 18(1):187. PubMed ID: 29439670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity.
    Liu L; Chen J; Zhang H; Ye J; Moore C; Lu C; Fang Y; Fu YX; Li B
    Nat Cancer; 2022 Apr; 3(4):437-452. PubMed ID: 35393580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized neoantigen vaccine enhances the therapeutic efficacy of bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer.
    Lin X; Tang S; Guo Y; Tang R; Li Z; Pan X; Chen G; Qiu L; Dong X; Zhang L; Liu X; Cai Z; Xie B
    Cancer Immunol Immunother; 2024 Jan; 73(2):26. PubMed ID: 38280084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD40 and CD80/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1
    Yamauchi T; Hoki T; Oba T; Kajihara R; Attwood K; Cao X; Ito F
    Cancer Immunol Immunother; 2022 Jan; 71(1):137-151. PubMed ID: 34037810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cloning variable region genes of clonal lymphoma immunoglobulin for generating patient-specific idiotype DNA vaccine.
    Cha SC; Qin H; Sakamaki I; Kwak L
    Methods Mol Biol; 2014; 1139():289-303. PubMed ID: 24619688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion.
    D'Alise AM; Leoni G; De Lucia M; Langone F; Nocchi L; Tucci FG; Micarelli E; Cotugno G; Troise F; Garzia I; Vitale R; Bignone V; Di Matteo E; Bartolomeo R; Charych DH; Lahm A; Zalevsky J; Nicosia A; Scarselli E
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
    Rappaport AR; Kyi C; Lane M; Hart MG; Johnson ML; Henick BS; Liao CY; Mahipal A; Shergill A; Spira AI; Goldman JW; Scallan CD; Schenk D; Palmer CD; Davis MJ; Kounlavouth S; Kemp L; Yang A; Li YJ; Likes M; Shen A; Boucher GR; Egorova M; Veres RL; Espinosa JA; Jaroslavsky JR; Kraemer Tardif LD; Acrebuche L; Puccia C; Sousa L; Zhou R; Bae K; Hecht JR; Carbone DP; Johnson B; Allen A; Ferguson AR; Jooss K
    Nat Med; 2024 Apr; 30(4):1013-1022. PubMed ID: 38538867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.
    Lin Z; Jiang C; Wang P; Chen Q; Wang B; Fu X; Liang Y; Zhang D; Zeng Y; Liu X
    Theranostics; 2023; 13(12):4166-4181. PubMed ID: 37554274
    [No Abstract]   [Full Text] [Related]  

  • 14. Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma.
    Ramirez CA; Becker-Hapak M; Singhal K; Russler-Germain DA; Frenkel F; Barnell EK; McClain ED; Desai S; Schappe T; Onyeador OC; Kudryashova O; Belousov V; Bagaev A; Ocheredko E; Kiwala S; Hundal J; Skidmore ZL; Watkins MP; Mooney TB; Walker JR; Krysiak K; Gomez F; Fronick CC; Fulton RS; Schreiber RD; Mehta-Shah N; Cashen AF; Kahl BS; Ataullakhanov R; Bartlett NL; Griffith M; Griffith OL; Fehniger TA
    Blood Adv; 2024 Aug; 8(15):4035-4049. PubMed ID: 38713894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
    Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
    Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8
    Chen H; Li Z; Qiu L; Dong X; Chen G; Shi Y; Cai L; Liu W; Ye H; Zhou Y; Ouyang J; Cai Z; Liu X
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
    Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
    Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
    Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient.
    Gao S; Wang J; Zhu Z; Fang J; Zhao Y; Liu Z; Qin H; Wei Y; Xu H; Dan X; Yang L; Xu Q
    Immunotherapy; 2023 Feb; 15(2):57-69. PubMed ID: 36651232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.